Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 280-068-8 | CAS number: 82933-90-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The acute toxicity of substance FAT 20043 was determined according to in-house methods before the implementation of OECD guidelines. The methods are considered to be equivalent to current OECD guidelines. The acute oral LD50 of FAT 20043 in rats of both sexes observed over a period of 14 days is greater than 5000 mg/kg. The compound has therefore is not considered to cause acute toxicity to the rat by this route of administration.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1975
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Principles of method if other than guideline:
- To identify LD50 of FAT 20043/E
- GLP compliance:
- no
- Test type:
- standard acute method
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: 6 weeks
- Weight at study initiation: average body weight of 170 g. (males) and 145 g. (females)
- Fasting period before study: 18 h
- Housing: Rats were caged singly and kept in a room
- Diet: ad libitum (Oakes Special Diet with added l/it. E)
- Water: ad libitum
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21 ± 2
- Photoperiod (hrs dark / hrs light): 12 hours artificial light and 12 hours darkness in each 24 hour period - Route of administration:
- oral: gavage
- Vehicle:
- water
- Remarks:
- tap water
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 25 % w/v
MAXIMUM DOSE VOLUME APPLIED: 20 ml/kg (equivalent to 5 g/kg of compound) - Doses:
- 20 ml/kg (equivalent to 5 g/kg of compound)
- No. of animals per sex per dose:
- 5
- Control animals:
- not specified
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: No data
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, mortality - Statistics:
- Not specified
- Preliminary study:
- None
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 5 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- No deaths occurred during the 14 day observation period.
- Clinical signs:
- No clinical symptoms were recorded during the 14 day observation period.
- Body weight:
- None
- Gross pathology:
- At autopsy no changes in organs or tissues caused by the administration of the test compound were seen.
- Other findings:
- None
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- The acute oral median lethal dose (LD50) of FAT 20043/B in rats is greater than 5000 mg/kg. body weight.
- Executive summary:
The compound FAT 20043/B was tested on 10 healthy Sprague-Dawley rats (5 males/ 5 females), aged 6 weeks having average body weight of 170g (male) and 145 g (female). Rats were caged singly and kept in a room maintained at a temperature of 21 °C with 12 hour light/dark period. A 25 % w/v suspension of the compound in tap-water was administered as a single dose by gavage to rats which had been fasted for 18 hours, at a dose rate of 20 ml/kg (equivalent to 5000 mg/kg of compound). After administration of the compound, the animals were observed for 14 days. Deaths and clinical symptoms were recorded. At the end of the observation period, surviving animals were killed by exsanguination under ether anaesthesia and an autopsy performed. No clinical symptoms were recorded and no deaths occurred during the 14 day observation period. At autopsy no changes in organs or tissues caused by the administration of the test compound were seen. The acute oral LD50 of FAT 20043/B in rats of both sexes observed over a period of 14 days is greater than 5000 mg/kg. The compound has therefore is not considered to cause acute toxicity to the rat by this route of administration.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 5 000 mg/kg bw
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Data waiving:
- other justification
- Justification for data waiving:
- other:
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- the study does not need to be conducted because the substance does not meet the criteria for classification as acute toxicity or STOT SE by the oral route and no systemic effects have been observed in in vivo studies with dermal exposure (e.g. skin irritation, skin sensitisation)
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Oral:
A study was performed in 1975 to assess the toxicity of the test substance FAT 20043/B according to in-house methods before the implementation of OECD guidelines. The methods are considered to be equivalent to todays OECD guidelines. The compound FAT 20043/B was tested on 10 healthy Sprague-Dawley rats (5 males/ 5 females), aged 6 weeks having average body weights of 170 g (males) and 145 g (females), respectively. The dose was applied as a single dose by gavage to rats which had been fasted for 18 hours, at a dose rate of 20 ml/kg (equivalent to 5000 mg/kg of compound). No clinical symptoms were recorded and no deaths occurred during the 14 day observation period. At autopsy no changes in organs or tissues caused by the administration of the test compound were seen. Therefore, the acute oral LD50 of FAT 20043/B in rats of both sexes observed over a period of 14 days is greater than 5000 mg/kg. The compound has therefore is not considered to cause acute toxicity to the rat by this route of administration. In another similar study the compound FAT 20043/A was tested on 40 Tif. RAI rats (20 males/ 20 females), aged 6 to 7 weeks old and weighed 160 to 180 g. The animals were treated at a concentration 4640, 6000, 6800, 7750 mg/kg. Within 2 hours after treatment the rats in all dosage groups showed sedation, dyspnoea, exophthalmos, curved position and ruffled fur. These symptoms became more accentuated as the dose was increased. The surviving animals had recovered within 7 to 8 days. They were secrified and autopsied after an observation period of 14 days. On autopsy no substance related gross organ changes were seen. The LD50 was calculated by probit analysis method. The acute oral LD50 of FAT 20043/A in rats of both sexes observed over a period of 14 days is 6519 (6143-6918) mg/kg based on the test material and 2933 mg/kg bw based on the active ingredient .The compound has therefore is not considered to cause acute toxicity to the rat by this route of administration. Taking both results into consideration, the test substance is judged to cause no acute oral toxicity up to 2000 mg/kg bw. It is most likely that even higher doses of the purified chemical are not of acute toxicity as demonstated by the key study selected. Why the test sample fomulation of the second study demonstrated higher toxicity while having a lower test substance concentration remains elusive.
Inhalation:
Currently no study to assess the acute inhalation toxicity potential of Acid Red 183 is available. However, the vapour pressure for the substance can be considered low owing to the high melting point (>350 °C). Hence, the substance is considered to have low volatility. Synthesis and spray drying of this chemical is performed in a closed process; the final product consists of non-dusty granules. Hence, the use of this substance will not result in aerosols, particles or droplets of an inhalable size, so exposure to humans via the inhalation route will be unlikely to occur. Based on column 2, ‘Specific rules for adaptation from column 1’ of the table given in REACH Annex VII, the study on acute inhalation toxicity only needs to be conducted if an exposure via inhalation is to be expected, based on vapour pressure and/or the likelihood of an exposure to aerosols, particles or droplets. Referring to the expected low volatility of the substance, the fact that the chemical is imported into the EU in a formulated form as a dust-free powder or as a granulate, the exposure via inhalation is considered to be unlikely. Further, the chemical is found to have water solubility of 41.2 g/L, hence in the case of dust of the substance entering the respiratory tract, it will be trapped in the mucus and cleared, thereby further limiting the absorption. The chemical showed low toxicity potential in the available acute oral toxicity studies (LD50: >5000 mg/kg bw), with no mortality or systemic toxicity being seen, hence it does not need to be classified STOT SE and low toxicity is expected for this chemical via the inhalation route. Taking into consideration the above arguments, low toxicity potential is expected on acute exposure of Acid Red 183 via inhalation route and hence testing by the inhalation route was considered scientifically not necessary.
Dermal:
The molecular weight of Acid Red 183 is 582.8 g/mol, indicating it being large for dermal absorption. It has water solubility of 41.2 g/L and n-octanol/water partition coefficient (log P) of -2.35, indicating it being too hydrophilic to cross the lipid rich environment of the stratum corneum. Hence, the dermal uptake for the substance will be low.The chemical showed low toxicity potential in the available acute oral toxicity studies (LD50>5000 mg/kg bw), with no mortality or systemic toxicity being seen upto 5000 mg/kg bw, hence it does not need to be classified as STOT SE. Similarly, absence of systemic toxicity in skin irritation and sensitisation studies, further supports the conclusion that no adverse effects are expected for the chemical via the dermal route. Further, experience with similar chemical substances has demonstrated that it is very unlikely that toxicity related to the intrinsic properties of the chemical only show up upon dermal exposure and not after systemic application. Taking above arguments into account, low toxicity is expected on acute dermal exposure of Acid Red 183 and testing by the dermal route was considered scientifically not necessary.
Justification for classification or non-classification
Based on the observed LD50 of >5000 mg/kg bw in acute oral studies, the test substance does not need to be classified according to EU Classification, Labelling and Packaging of Substances and Mixtures (CLP) Regulation (EC) No. 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.